Showing 4431-4440 of 9821 results for "".
- Novan: Positive Topline Results with Fungicidal SB208 in Phase 2 Trialhttps://practicaldermatology.com/news/nolan-positive-topline-results-with-fungicidal-sb208-in-phase-2-trial/2458222/Novan, Inc. has announced positive topline results from their Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan’s SB208 Gel, at bo
- FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to Humira Prescribing Informationhttps://practicaldermatology.com/news/fda-approves-addition-of-moderate-to-severe-fingernail-psoriasis-data-to-humira-prescribing-information/2458232/The FDA approved the inclusion of moderate to severe fingernail psoriasis data in AbbVie's Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Humira is the first biologic treatment with data on fingernail psoriasis in its US prescribing
- Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitishttps://practicaldermatology.com/news/positive-results-announced-from-sebuderm-gel-study-in-treatment-of-seborrheic-dermatitis/2458237/The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI.
- AAD Throws Some Shade At 26 Schools With 2017 Shade Structure Grantshttps://practicaldermatology.com/news/aad-throws-some-shade-at-26-schools-with-2017-shade-structure-grants/2458245/The American Academy of Dermatology (AAD) awarded shade structure grants to 26 schools and non-profit organizations across the country. Since its launch in 2000, the AAD’s Shade Structure Grant Program has awarded 350 shade structure grants, which pr
- Seventeen Percent of Teens Report Excessive Sweatinghttps://practicaldermatology.com/news/seventeen-percent-of-teens-report-excessive-sweating/2458251/More teens than previously thought may experience excessive, uncontrollable sweating, according to data collected by International Hyperhidrosis Society researchers and presented at the recent American Academy of Dermatology’s (AAD) 2017 Annual Me
- A “C” Change: Introducing Exuviance's New Vitamin C Serum Capsuleshttps://practicaldermatology.com/news/a-c-change-introducing-exuviances-new-vitamin-c-serum-capsules/2458250/Coming this summer, Exuviance’s AF Vitamin C20 serum capsules promise maximum delivery of actives. Unlike many existing products, Exuviance AF Vitamin C20 Serum comes in capsule form. Other types of packaging expose vitamin C to light, air, o
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- Galderma's OTC Differin Gel Hits Store Shelveshttps://practicaldermatology.com/news/galdermas-otc-differin-gel-hits-stores/2458299/Galderma’s Differin Gel 0.1% (adapalene) is now available over the counter (OTC) at major retail and drug stores. Galderma officially launched the gel at a New York City media fete, and the skin care co
- Specialty Pharma Industry Vet Charles Gregory Vontz Joins BioPharmX Board of Directorshttps://practicaldermatology.com/news/specialty-pharma-industry-vet-charles-gregory-vontz-joins-biopharmx-board-of-directors/2458311/Charles "Greg" Vontz is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17. Vontz's appointment expands the board to four directors, three of whom are independent.
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro